Moderna vaccine initial trial shows promising results
The vaccine will now advance to a second trial involving hundreds of volunteers
The pharmaceutical company Moderna announced Monday that its vaccine, the first to be tested in people, appears to be safe and is stimulating an immune response against the novel virus.
The trial's results are base around eight people who received doses of the virus beginning in March. The volunteers, who were healthy, produced antibodies that were determined to be effective in preventing the virus from replicating.
The company will now proceed along an accelerated timetable by moving to immediately begin a second phase involving 600 people. The third trial will begin in July, and will involve thousands of healthy volunteers.
Moderna's chief medical officer is hopeful that, if these trials continue to go well, a vaccine could be widely available by the end of this year or in early 2021.
Moderna's stock jumped 40% on Monday morning, as a result of this news.
News, Not Noise
- James Comey’s 'no clue' routine on Russia probe exposes an FBI in distress
- House Majority Leader expects quick passage of $2.2 trillion stimulus bill
- Peter King: 'McConnell doesn't know what he's talking about' opposing federal COVID aid for states
- Attorney demands Biden retract 'false accusation' that Kenosha shooter is 'white supremacist'
- Here's how Biden wants Commission on Presidential Debates to change format